The pathophysiology of endothelial function in pregnancy and the usefulness of endothelial markers

Biomedical Papers

Volumn 155, Issue 4, 2011, Pages 219-224

  Slavika, Ludek ^a   Prochazkova, Jana ^a   Prochazka, Martin ^a   Simetka, Ondrej ^b   Hlusi, Antonin ^a   Ulehlova, Jana ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

Author keywords

Coagulation activation markers; Endothelial dysfunction; Endothelium; Matrix metalloproteinases; Pregnancy complications

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; EXTRACELLULAR MATRIX; FEMALE; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; PREGNANCY; PREGNANCY COMPLICATIONS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84255182734     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2011.031     Document Type: Article

References (47)

1. Machac S, Lubusky M, Prochazka M, Streda R. Prevalence of inheritedthrombophilia in patients with severe ovarian hyperstimulationsyndrome. Biomed Pap Med Fac Univ Palacky OlomoucCzech Repub 2006;150(2):289-92.
2. Prochazka M, Lubusky M, Slavik L, Hrachovec P, Zielina P, KudelaM, Lindqvist PG. Selected pregnancy variables in women withplacental abruption. Biomed Pap Med Fac Univ Palacky OlomoucCzech Repub 2006;150(2):271-3.
3. Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sampol J, Dignat-George F. In vitrogeneration of endothelial microparticles and possible prothromboticactivity in patients with lupus anticoagulant. J Clin Invest 1999;104(1):93-102.
4. Leroyer AS, Tedgui A, Boulanger CM. Role of microparticles inatherothrombosis. J Intern Med 2008;263(5):528-37.
5. Bulava A, Slavík L, Fiala M, Heinc P, Skvarilova M, Lukl J, KrcováV, Indrák K. Endothelial damage and activation of the hemostaticsystem during radiofrequency catheter isolation of pulmonaryveins. J Interv Card Electrophysiol 2004;10(3):271-9.
6. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles:a potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006;48(2):180-6.
7. Canault M, Leroyer AS, Peiretti F, Lesèche G, Tedgui A, Bonardo B, Alessi MC, Boulanger CM, Nalbone G. Microparticles of humanatherosclerotic plaques enhance the shedding of the tumor necrosisfactor-alpha converting enzyme/ADAM17 substrates, tumornecrosis factor and tumor necrosis factor receptor-1. Am J Pathol 2007;171(5):1713-23.
8. Slavik L, Krcova V, Hlusi A, Prochazkova J, Prochazka M, Ulehlova J, Indrak K. Molecular pathophysiology of thrombotic states andtheir impact to laboratory diagnostics. Biomed Pap Med Fac UnivPalacky Olomouc Czech Repub 2009;153(1):19-25.
9. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogenactivator inhibitor-1, inflammation, obesity, insulin resistance andvascular risk. J Thromb Haemost 2003;1(7):1575-9.
10. Doggen CJ, Bertina RM, Cats VM, Reitsma PH, Rosendaal FR. The 4G/5G polymorphism in the plasminogen activator inhibitor-1gene is not associated with myocardial infarction. Thromb Haemost 1999;82(1):115-20.
11. Vidal C, Spaulding C, Picard F, Schaison F, Melle J, Weber S, Fontenay-Roupie M. Flow cytometry detection of platelet procoagulationactivity and microparticles in patients with unstable anginatreated by percutaneous coronary angioplasty and stent implantation. Thromb Haemost 2001;86(3):784-90.
12. Beekman B, Drijfhout JW, Bloemhoff W, Ronday HK, Tak PP, te Koppele JM. Convenient fluorometric assay for matrix metalloproteinaseactivity and its application in biological media. FEBSLett 1996;390(2):221-5.
13. Essayagh S, Xuereb JM, Terrisse AD, Tellier-Cirioni L, Pipy B, Sie P. Microparticles from apoptotic monocytes induce transientplatelet recruitment and tissue factor expression by cultured humanvascular endothelial cells via a redoxsensitive mechanism. ThrombHaemost 2007;98:831-7.
14. Satta N, Freyssinet JM, Toti F. The significance of human monocytethrombomodulin during membrane vesiculation and afterstimulation by lipopolysaccharide. Br J Haematol 1997;96:534-42.
15. Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat-GeorgeF. Interaction of endothelial microparticles with monocytic cells invitro induces tissue factor-dependent procoagulant activity. Blood 2002;99:3962-70.
16. Perez-Casal M, Downey C, Fukudome K, Marx G, Toh CH. Activated protein C induces the release of microparticle-associatedendothelial protein C receptor. Blood 2005;105:1515-22.
17. Bouzeghrane F, Zhang X, Gevry G, Raymond J. Deep vein thrombosisresolution is impaired in diet-induced type 2 diabetic mice. JVasc Surg 2008;48(6):1575-84.
18. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expressionof matrix metalloproteinases and matrix degrading activity in vulnerableregions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.
19. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atheroscleroticlesions. Association of active enzyme synthesis with unstableangina. Circulation 1995;91:2125-31.
20. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T, Welgus HG,Alpers CE, Clowes AW. Interstitial collagenase (MMP-1) expressionin human carotid atherosclerosis. Circulation 1995;92:1393-8.
21. Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, Stetler-Stevenson WG, Froehlich J, Lakatta EG. Increased expression of72-kd type IV collagenase (MMP-2) in human aortic atheroscleroticlesions. Am J Pathol 1996;148:121-8.
22. Galis ZS, Sukhova GK, Libby P. Microscopic localization of activeproteases by in situ zymography: detection of matrix metalloproteinaseactivity in vascular tissue. FASEB J 1995;9:974-80.
23. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, Sharifi B, Shah PK. Oxidized low-density lipoprotein regulates matrixetalloproteinase-9 and its tissue inhibitor in human monocytederivedmacrophages. Circulation 1999;99:993-8.
24. Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, Fishbein MC, Kaul S, Cercek B, Sharifi B, Shah PK. Membranetype 1 matrix metalloproteinase expression in human atheroscleroticplaques: evidence for activation by proinflammatory mediators. Circulation 1999;99:3103-9.
25. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, Chai NN, Xu XP, Jovinge S, Shah PK, Libby P. Inflammatorycytokines and oxidized low density lipoproteins increase endothelialcell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 1999;274:11924-9.
26. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, HortonDB, Kilbride M, Breitbart RE, Chun M, Schönbeck U. Expressionof neutrophil collagenase (matrix metalloproteinase-8) in humanatheroma: a novel collagenolytic pathway suggested by transcriptionalprofiling. Circulation 2001;104:1899-904.
27. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrouscaps of atherosclerotic plaques. Potential role of matrix degradingmetalloproteinases and implications for plaque rupture. Circulation 1995;92:1565-9.
28. Shah PK. Role of inflammation and metalloproteinases in plaquedisruption and thrombosis. Vasc Med 1998;3:199-206.
29. Sukhova GK, Schönbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P. Evidence for increased collagenolysis byinterstitial collagenases-1 and -3 in vulnerable human atheromatousplaques. Circulation 1999;99:2503-9.
30. Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P. Circumferentialstress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler ThrombVasc Biol 1996;16:1070-3.
31. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases inducedin vitro by cytokines and in regions of human atheroscleroticlesions. Ann NY Acad Sci 1995;748:501-7.
32. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutivelyproduce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995;92:402-6.
33. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heatshock protein 60 localizes in human atheroma and regulates macrophagetumor necrosis factor-alpha and matrix metalloproteinaseexpression. Circulation 1998;98:300-7.
34. Mach F, Schönbeck U, Fabunmi RP, Murphy C, Atkinson E, Bonnefoy JY, Graber P, Libby P. T lymphocytes induce endothelialcell matrix metalloproteinase expression by a CD40Ldependentmechanism: implications for tubule formation. Am J Pathol 1999;154:229-38.
35. Schönbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, Libby P. Regulation of matrix metalloproteinase expressionin human vascular smooth muscle cells by T lymphocytes:a role for CD40 signaling in plaque rupture? Circ Res 1997;81:448-54.
36. Wallner K, Li C, Shah PK, Fishbein MC, Forrester JS, Kaul S, Sharifi BG. Tenascin-C is expressed in macrophage-rich humancoronary atherosclerotic plaque. Circulation 1999;99:1284-9.
37. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheromaand regulation of their production in smooth muscle cells. JClin Invest 1998;102:576-83.
38. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, Ridker PM, Libby P, Chapman HA. Cystatin C deficiencyin human atherosclerosis and aortic aneurysms. J Clin Invest 1999;104:1191-7.
39. Sheppard SJ, Khalil RA. Risk factors and mediators of the vasculardysfunction associated with hypertension in pregnancy. CardiovascHematol Disord Drug Targets 2010;10(1):33-1.
40. Tamura T, Nakanishi T, Kimura Y, Hattori T, Sasaki K, Norimatsu H, Takahashi K, Takigawa M. Nitric oxide mediates interleukin-1-induced matrix degradation and basic fibroblast growth factorrelease in cultured rabbit articular chondrocytes: a possible mechanismof pathological neovascularization in arthritis. Endocrinology 1996;137:3729.
41. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J. Biol. Chem 1999;274:21491.
42. Morgunova E, Tuuttila A, Bergmann U, Isupov M, Lindqvist Y, Schneider G, Tryggvason K. Structure of human pro-matrixmetalloproteinase-2: activation mechanism revealed. Science 1999;284:1667.
43. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, JacksonG, Harper J, Tamvakopoulos G, Moses MA. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype ina tumor model. Proc Natl Acad Sci USA 2000;97:3884.
44. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinasesin urine of cancer patients. Cancer Res 1998;58:1395.
45. Matrisian, L.M. The matrix-degrading metalloproteinases. BioEssays 1992;14:455.
46. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3(stromelysin) activates the precursor for the human matrix metalloproteinase9. J Biol Chem 1992;267:3581.
47. Sires UI, Griffin GL, Broekelmann TJ, Mecham RP, Murphy G, Chung AE, Welgus HG, Senior RM. Degradation of entactin bymatrix metalloproteinases. Susceptibility to matrilysin and identificationof cleavage sites. J Biol Chem 1993;268:2069.